January 28, 2019 7:29am
The problem is a hangover that clouds the market and conversely the sector
After last week’s 2 bottom ups (positive closes), 2 empty glasses (negative closes) and a holiday
Pre-open indication: 1 SELL and 3 TRADEs
I answer one question, in which company should investors put, keep and commit their money!
I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.
U.S. stock index futures are dipping
Dow futures are DOWN -0.38% (-93 points) and NASDAQ futures are DOWN -0.47% (-32 points)
U.S. stock index futures pointed to a lower open on Monday as investors weighed the prospect of another government shutdown.
European markets started the week on a negative note as investors kept eyes on Brexit developments
Asian markets closed lower following a turbulent trading session
Data docket: A reading of business activity is due, with the Federal Reserve of Chicago’s national activity index due at 8:30 a.m. ET, while a Dallas Fed manufacturing survey is due at 10 a.m.
The iShares Nasdaq Biotechnology (IBB) is NOT indicating
The SPDR S&P Biotech ETF (XBI) is NOT indicating
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating
The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.5% DOWNSIDE
Investors and traders are worried over the new talk of another shut-down having not even started the re-open and further trade talks between China and the U.S., which are set to start later this week.
New week, different game – wrack them up and break!
Friday’s evening post, “if valuation is driving your views of the future, instead of the future driving your views on valuation, you’re doing it wrong.”
I also stated, “The remainder of the month’s trading sessions will be critical for the RegMed sector which will establish whether market reaction to recent events is temporary or NOT maybe short-lived; however, the “antics” of pricing, volume and volatility are dependent on traders who are “picky” as their purchasing habits while algorithms initiate signals based on “rules” – with 99% of investors DON’T understand!”
Friday night’s percentage (%) indicators:
- The range of the 32 upside was +0.35% (RGNX) to +7.51% (CUR +$0.0279) while the 10 downside ranged from -0.06% (VCEL) to -7.82% (VSTM) with 3 flat close (FIXX, ONVO and RENE.L).
Volume stat: extremely low
- 11 out of the 32 upside had higher (than the 3 month average) volume
- 1 out of the 10 downside experienced greater volume (than the 3 month average) volume
Running the month:
- In 17 sessions in January – there was 11 positive closes, 1 holiday and 6 negative closes – so far!
Companies in my headlights – It’s your decision; I provide an idea and context:
Cellectis (CLLS) closed up +$0.78 to $16.31 after Thursday’s -$0.16 to $15.53, Wednesday’s -$0.19 to $15.69 following last Tuesday’s as last Monday was a market holiday. There is a pre-market negative -$0.06 or -0.37% indication - BUY to SELL;
CRISPRS Therapeutics (CRSP) closed up +$0.91 to $33.20 after Thursday’s +$0.89 to $32.29. Wednesday’s -$1.68 to $31.40, Tuesday’s -$4.05 to $33.0-8, last Monday was a market holiday and the previous Friday’s +$1.25 to $37.13 – TRADE;
Editas Medicine (EDIT) closed up +$0.13 to $21.46 after Thursday’s +$1.23 to $21.33, Wednesday’s -$0.85 to $20.10, Tuesday’s -$5.19 to $20.95 (after news of their CEOs resignation following the CFO and CMO leaving), last Monday was a market holiday and the previous Friday’s -$0.07 to $26.14– TRADE;
Intellia Therapeutics (NTLA) closed up +$0.38 to $14.76 after Thursday’s +$0.60 to $14.38, Wednesday’s -$0.38 to $13.68, Tuesday’s -$1.04 to $14.16, last Monday was a market holiday and the previous Friday’s +$0.28 to $15.20 – TRADE;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.